The company aims to maintain study integrity by not conducting interim reviews for ALTITUDE AD. They plan to release data at the study end and cannot disclose ARIA results until unblinded. The enrollment rate for Phase 2 is exceeding expectations, and they target patients with mild cognitive impairment for the study.